肺高血压中T细胞的微环境调节
Lydie Plecitá-Hlavatá1, Andrea Brázdová2,3, Monika Křivonosková1,4
1Laboratory of Pancreatic Islet Research, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Frontiers in immunology
|July 27, 2023
概括
肺高血压 (PH) 涉及纤维细胞激活T细胞的炎症. 这项研究表明PH纤维细胞促进T细胞炎症和增殖,有助于在肺高血压中血管重塑.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 肺高血压 (PH) 的特点是肺动脉重塑和周围血管炎症.
- 冒险体内的纤维细胞通过分泌细胞因子和化学因子,促进炎症.
研究的目的:
- 调查PH动脉中的肺纤维细胞是否影响T细胞激活和极化.
- 了解纤维细胞衍生微环境在PH相关炎症中的作用.
主要方法:
- 牛肺动脉的单细胞RNA测序.
- 来自PH纤维细胞的条件介质暴露的T细胞的流细胞计和mRNA表达分析.
- 呼吸计分析以评估T细胞代谢功能.
主要成果:
- PH纤维细胞促进亲炎性T细胞表型,减少调节性T细胞 (Tregs).
- 暴露于PH纤维细胞受条件介质会增加IFNγ并降低IL4,IL10和TGFβ.
- 暴露于PH纤维细胞受条件介质的T细胞会诱导新陈代谢转变,增加增殖,并产生抗氧化状态.
结论:
- 肺纤维细胞创造了一个微环境,激活和分化T细胞,驱动PH的局部炎症.
- 这种纤维细胞介导的T细胞激活有助于在肺高血压中血管壁重塑.
相关概念视频
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Pulmonary Hypertension: Classification and Pathogenesis
227
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
227
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
206
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
206


